Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3833MR)

This product GTTS-WQ3833MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3833MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5384MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ7670MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ15665MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ298MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ1183MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABP 501
GTTS-WQ12757MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ5304MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ5844MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW